USA - NASDAQ:ZYBT - KYG989MS1016 - Common Stock
The current stock price of ZYBT is 2.21 USD. In the past month the price increased by 5.94%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 50.5 | 771.92B | ||
| JNJ | JOHNSON & JOHNSON | 18.07 | 451.72B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 18.73 | 257.78B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 14.09 | 241.39B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 13.33 | 230.37B | ||
| MRK | MERCK & CO. INC. | 11.31 | 217.43B | ||
| PFE | PFIZER INC | 7.31 | 140.89B | ||
| SNY | SANOFI-ADR | 11.52 | 124.09B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 6.39 | 87.52B | ||
| GSK | GSK PLC-SPON ADR | 9.81 | 88.38B | ||
| ZTS | ZOETIS INC | 23.55 | 64.91B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 50.48 | 44.64B |
Zhengye Biotechnology Holding Ltd. engages in the manufacture and sale of veterinary vaccines. The company is headquartered in Jilin, Jilin and currently employs 277 full-time employees. The company went IPO on 2025-01-07. The firm markets a diverse range of vaccines, including vaccines for swine, cattle, goats, sheep, poultry, and dogs. The firm owns about 44 veterinary vaccines in its product portfolio, which cover veterinary vaccines for livestock, including monovalent vaccine, polyvalent vaccine, combined vaccine and combined and polyvalent vaccine. The firm also engages in vaccines for treating livestock. The firm mainly conducts its business in the domestic market. The firm mainly conducts its business in the domestic and overseas market.
ZHENGYE BIOTECHNOLOGY HOLDIN
No.1 Lianmeng Street, Jilin Economic &, Technical Development Zone
Jilin JILIN CN
Employees: 277
Zhengye Biotechnology Holding Ltd. engages in the manufacture and sale of veterinary vaccines. The company is headquartered in Jilin, Jilin and currently employs 277 full-time employees. The company went IPO on 2025-01-07. The firm markets a diverse range of vaccines, including vaccines for swine, cattle, goats, sheep, poultry, and dogs. The firm owns about 44 veterinary vaccines in its product portfolio, which cover veterinary vaccines for livestock, including monovalent vaccine, polyvalent vaccine, combined vaccine and combined and polyvalent vaccine. The firm also engages in vaccines for treating livestock. The firm mainly conducts its business in the domestic market. The firm mainly conducts its business in the domestic and overseas market.
The current stock price of ZYBT is 2.21 USD. The price decreased by -4.74% in the last trading session.
ZYBT does not pay a dividend.
ZYBT has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
ZHENGYE BIOTECHNOLOGY HOLDIN (ZYBT) currently has 277 employees.
ZHENGYE BIOTECHNOLOGY HOLDIN (ZYBT) has a market capitalization of 104.73M USD. This makes ZYBT a Micro Cap stock.
ChartMill assigns a technical rating of 1 / 10 to ZYBT.
ChartMill assigns a fundamental rating of 5 / 10 to ZYBT. ZYBT has only an average score on both its financial health and profitability.
Over the last trailing twelve months ZYBT reported a non-GAAP Earnings per Share(EPS) of 0.12. The EPS increased by 21.94% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 12.95% | ||
| ROA | 7.96% | ||
| ROE | 13.83% | ||
| Debt/Equity | 0.02 |